Crown Bioscience, a leading global drug discovery and development service company with one of its R&D centres in Taicang, Jiangsu, China, has announced that an agreement has been reached with the National Resource Center for Mutant Mice (NRCMM), in Nanjing, Jiangsu Province, China. The strategic partnership will focus on developing new experimental cancer models to advance translational medical research and the treatment of cancers.
The immediate focus of the research collaboration will be to build new experimental models for cancer research leveraging the proprietary technologies of both companies. The collaboration is expected to significantly expand the research capabilities of both organisations in translational oncology and will thus benefit the global research community fighting cancers.
Crown Bioscience is a premier service provider of translational oncology and metabolic diseases platforms providing focused disease models. It has one of the largest and most advanced translational oncology platforms featuring fully annotated collections of proprietary patient derived xenograft (PDX) models (>1000). NRCMM is a leading research organisation specialised in genetically engineered mutant mouse (GEMM), with vast resources, including a large collection of GEMMs, many of which mimic human cancers. Both parties have complimentary expertise and experience in oncology and GEMMs, and therefore the established joint effort will have great synergy in creating new translational oncology platforms based on GEMMs.
The collaboration will offer significantly expanded new mouse cancer and leukaemia models based on GEMM as well as new human xenografts, in addition to the current PDX and CDX platforms (cell line derived xenograft) at Crown and the current GEMMs at NRCMM. In particular, novel mouse strains with various humanisations could be particularly powerful tools for immune-oncology research and immunotherapy drug evaluations.
